Precision Monitoring of Immunosuppressive Agent Concentrations in Cardiac Tissue of Pediatric Heart Transplant Recipients

被引:0
|
作者
Hashimoto, Kazuhisa [1 ]
Kimura, Natsuka [2 ]
Narita, Jun [1 ]
Ishii, Ryo [1 ]
Hirose, Masaki [1 ]
Hayashi, Ken [1 ]
Nishino, Haruka [1 ]
Ueyama, Atsuko [1 ]
Ueda, Kazutoshi [1 ]
Yoshihara, Chika [1 ]
Kitabatake, Yasuji [1 ]
Nagai, Ryozo [3 ]
Aizawa, Kenichi [2 ]
Ishida, Hidekazu [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Pediat, Osaka, Japan
[2] Jichi Med Univ, Dept Pharmacol, Div Clin Pharmacol, Shimotsuke, Japan
[3] Jichi Med Univ, Shimotsuke, Japan
关键词
heart transplantation; immunosuppressive treatment; liquid chromatography-tandem mass spectrometry; therapeutic drug monitoring; PHARMACOKINETICS; TACROLIMUS;
D O I
10.1111/petr.70092
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Management of immunosuppressive therapy after heart transplantation is typically guided by blood trough levels. Although tissue concentrations of immunosuppressive agents reportedly correlate with acute rejection in liver and kidney allografts, data in pediatric heart transplant recipients remain limited. Methods We enrolled 41 pediatric heart transplant recipients who underwent follow-up endomyocardial biopsy (EMB) between July 2021 and December 2023. For nine of those patients, serial data were collected up to 24 weeks post-transplantation. Myocardial tissue concentrations of tacrolimus (TAC), everolimus (EVR), mycophenolic acid (MPA), and mycophenolic acid glucuronide (MPAG) were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS), while blood concentrations were quantified by LC-MS/MS or immunoassays. Results Significant correlations were observed between myocardial and blood concentrations at EMB for TAC (r = 0.73, p < 0.0001), MPA (r = 0.79, p < 0.0001), and MPAG (r = 0.50, p < 0.0001). However, for EVR there was no significant correlation. Longitudinal analysis demonstrated that the tissue-to-blood TAC and EVR ratios decreased with age. No significant rejection events were observed during the study period, precluding the analysis of rejection risk. Conclusion Myocardial TAC, MPA, and MPAG concentrations are associated with blood levels, whereas those of EVR showed no significant correlation. Further, the tissue perfusion efficiencies of TAC and EVR decreased with age. This study highlights the value of LC-MS/MS for immunosuppressant monitoring after pediatric heart transplantation.
引用
收藏
页数:10
相关论文
共 50 条
  • [11] Kidney and Liver Tissue Tacrolimus Concentrations in Adult Transplant Recipients-The Influence of the Whole Blood and Tissue Concentrations on Efficiency of Treatment during Immunosuppressive Therapy
    Bodnar-Broniarczyk, Magdalena
    Durlik, Magdalena
    Baczkowska, Teresa
    Czerwinska, Katarzyna
    Marszalek, Ryszard
    Pawinski, Tomasz
    PHARMACEUTICS, 2021, 13 (10)
  • [12] Cardiac Surgery is Successful in Heart Transplant Recipients
    Holmes, Timothy R.
    Jansz, Paul C.
    Spratt, Phillip
    Macdonald, Peter S.
    Dhital, Kumud
    Hayward, Christopher
    Arndt, Grace T.
    Keogh, Anne
    Hatzistergos, Joanna
    Granger, Emily
    HEART LUNG AND CIRCULATION, 2014, 23 (08) : 703 - 710
  • [13] TISSUE POLYPEPTIDE SPECIFIC ANTIGEN, NEOPTERIN, AND CRP FOR MONITORING HEART-TRANSPLANT RECIPIENTS
    VOGL, M
    ANDERT, SE
    MULLER, MM
    CLINICAL BIOCHEMISTRY, 1995, 28 (03) : 291 - 295
  • [14] Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients
    Job, Kathleen M.
    Roberts, Jessica K.
    Enioutina, Elena Y.
    IIIamola, Silvia M.
    Kumar, Shaun S.
    Rashid, Jahidur
    Ward, Robert M.
    Fukuda, Tsuyoshi
    Sherbotie, Joseph
    Sherwin, Catherine M.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (07) : 747 - 765
  • [15] Limited Sampling Strategies for Monitoring Tacrolimus in Pediatric Liver Transplant Recipients
    Delaloye, Jean-Romain
    Kassir, Nastya
    Lapeyraque, Anne-Laure
    Alvarez, Fernando
    Lallier, Michel
    Beaunoyer, Mona
    Labbe, Line
    Theoret, Yves
    Litalien, Catherine
    THERAPEUTIC DRUG MONITORING, 2011, 33 (04) : 380 - 386
  • [16] Post-transplant lymphoproliferative disorder in pediatric heart transplant recipients
    Manlhiot, Cedric
    Pollock-BarZiv, Stacey M.
    Holmes, Claire
    Weitzman, Sheila
    Allen, Upton
    Clarizia, Nadia A.
    Ngan, Bo-Yee
    McCrindle, Brian W.
    Dipchand, Anne I.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (06) : 648 - 657
  • [17] Emergency department utilization in pediatric heart transplant recipients
    Wittlieb-Weber, Carol A.
    Rossano, Joseph W.
    Weber, David R.
    Lin, Kimberly Y.
    Ravishankar, Chitra
    Mascio, Christopher E.
    Shaddy, Robert E.
    O'Connor, Matthew J.
    PEDIATRIC TRANSPLANTATION, 2017, 21 (04)
  • [18] Physiological Responses to Exercise in Pediatric Heart Transplant Recipients
    Bovard, Joshua M.
    De Souza, Astrid M.
    Harris, Kevin C.
    Human, Derek G.
    Hosking, Martin C. K.
    Potts, James E.
    Armstrong, Kathryn
    Sandor, George G. S.
    Cote, Anita T.
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2019, 51 (05) : 850 - 857
  • [19] NTproBNP as a marker of rejection in pediatric heart transplant recipients
    Knecht, Kenneth R.
    Alexander, Molly L.
    Swearingen, Christopher J.
    Frazier, Elizabeth A.
    PEDIATRIC TRANSPLANTATION, 2012, 16 (04) : 335 - 339
  • [20] Infectious risk in pediatric organ transplant recipients: Is it increased with the new immunosuppressive agents?
    Renoult, E
    Buteau, C
    Lamarre, V
    Turgeon, N
    Tapiero, B
    PEDIATRIC TRANSPLANTATION, 2005, 9 (04) : 470 - 479